Table 4

- Analysis of frequency of RPL5 genotype polymorphisms and HVT risk.

db SNP b153 v2GenotypePatientsControlP-value*Unadjusted OR [95% CI]
n (%)
rs138979590G/C250 (24.5)214 (25.2) Reference
G/T260 (25.5)210 (24.8)0.7081.06 [0.81-1.37]
G/C+G/T510 (50.0)424 (50.5)0.8421.03 [0.82-1.29]
rs558220259A/A442 (61.7)366 (64.8) Reference
A/G144 (20.1)113 (20.0)0.7641.06 [0.79-1.39]
G/G130 (18.2)86 (15.2)0.1731.25 [0.92-1.7]
rs576892621A/A466 (65.2)378 (67.0) Reference
A/G143 (20.0)112 (19.9)0.8621.04 [0.78-1.37]
G/G106 (14.8)74 (13.1)0.4131.16 [0.84-1.61]
rs182018447G/G458 (64.1)402 (71.2) Reference
G/A142 (19.9)113 (20.0)0.5431.10 [0.83-1.46]
A/A114 (16.0)50 (8.8)0.000*2.00 [1.39-2.86]
rs559377519A/A486 (63.7)404 (71.5) Reference
A/T148 (19.4)113 (20.0)0.5491.08 [0.82-1.43]
T/T98 (12.9)48 (8.5)0.004*1.69 [1.17-2.45]
  • * P-values were calculated by chi-square analyses; differences were statistically significant at p<0.05. OR: odds ratio, CI: confidence interval, HVT: hepatic vein thrombosis. Single-variant association analyses was performed.